XBIO vs DLXY Comparison

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Delixy Holdings Ltd a holding company. Through its subsidiary, it is principally engaged in the trading of oil-related products, which are broadly categorized into crude oil and oil-based products, including naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. These products are traded across multiple countries in Southeast Asia, East Asia, and the Middle East, and the Group has established a presence in the oil trading markets in these countries. The majority of the Group's revenue is generated from the trading of crude oil. Geographically, it derives maximum revenue from its business in East Asia.